Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Roche Holding Ltd.    ROG   CH0012032048

My previous session
Most popular
News SummaryMost relevantAll newsOfficial PublicationsSector newsTweetsMarketScreener Strategies

Roche : faces UK pricing row over multiple sclerosis drug Ocrevus

share with twitter share with LinkedIn share with facebook
share via e-mail
09/10/2018 | 01:14am CET
Logo of Swiss drugmaker Roche is seen at its headquarters in Basel

LONDON (Reuters) - Roche faces a fresh row over drug pricing in Britain, following a decision by the body responsible for medicine use within the state health service not to approve its drug Ocrevus for treating a highly disabling form of multiple sclerosis (MS).

In June, the National Institute for Health and Care Excellence (NICE) endorsed Ocrevus for relapsing-remitting MS - the most common type of the disease - but it has now rejected it for the rarer and more severe primary-progressive form of MS.

Ocrevus is the only available treatment for primary-progressive MS (PPMS), while there are several drugs for relapsing-remitting MS (RRMS), and Roche UK general manager Richard Erwin said Monday's decision was "devastating news" for patients.

It is not the first time the Swiss drugmaker has clashed with NICE, which determines if drugs are cost-effective enough to be used in the National Health Service (NHS) in England and Wales.

Roche has also battled to get a number of its cancer drugs approved by NICE in the past, prompting Chief Executive Severin Schwan to brand Britain's health system as "stupid" three years ago https://uk.reuters.com/article/us-roche-cancer-britain/roche-ceo-attacks-britains-stupid-cancer-drug-system-idUKKCN0R81J620150908.

In the case of Ocrevus, Roche said it had reached a stalemate because the authorities were not allowed to even consider a confidential discounted price for using the drug in PPMS that was different from the RRMS price.

That is a problem because the evidence showing the benefit of Ocrevus in PPMS is not as compelling as in RRMS, so a lower price would be needed to reach NICE cost-effectiveness thresholds.

The restriction meant NICE had to consider the existing RRMS approved price for the PPMS indication and this was deemed too expensive. In a statement, NICE said the size and duration of the drug's benefits in PPMS were uncertain and it could not be considered an acceptable use of NHS resources.

Worldwide, Ocrevus has proved to be a big commercial success for Roche, with sales topping $1 billion in the first half of 2018, and the company said it hoped an agreement could be reached for its use within the NHS.

"Roche is confident that given the flexibility to offer an indication-specific price, we will be able to offer a price that is deemed cost-effective for PPMS," the company said.

(Reporting by Ben Hirschler; Editing by Mark Potter)

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on ROCHE HOLDING LTD.
11/13Roche's Tecentriq Gets FDA Priority Review With Celgene's Abraxane
11/13ROCHE : FDA Grants Priority Review to Genentech’s Tecentriq in Combination..
11/12Takeda sets vote date, aims to close $62 billion Shire deal January 8
11/12Takeda sets vote date, aims to close $62 billion Shire deal on January 8
11/01GENENTECH : to Present New Data from Its Industry-Leading Hematology Portfolio a..
10/31ROCHE : Phase III Data Showed That Venclexta Plus Gazyva Reduced the Risk of Dis..
10/30Halozyme Licenses Enhanze to Roche for New Targets
10/29Drugmakers tout new medicines as eye disease battle intensifies
10/29SHIONOGI : aims to double flu-drug market with FDA-approved treatment
10/27ROCHE : New Stairway Study Data Shows Potential for Extended Durability with Far..
More news
News from SeekingAlpha
11/14BIOTECH BIO SERIES #4 : Regeneron Is Not Done 
11/13Express Scripts launches new formulary aimed at reducing drug costs 
11/13ClearBridge Appreciation Strategy Portfolio Manager Commentary Q3 2018 
11/13FDA accepts Roche's application for Tecentriq + Abraxane in first-line TNBC 
11/05Novartis backs away from U.S. marketing application for Rituxan biosimilar 
Financials (CHF)
Sales 2018 56 769 M
EBIT 2018 19 421 M
Net income 2018 13 118 M
Debt 2018 4 844 M
Yield 2018 3,53%
P/E ratio 2018 15,98
P/E ratio 2019 15,56
EV / Sales 2018 3,85x
EV / Sales 2019 3,71x
Capitalization 213 B
Duration : Period :
Roche Holding Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ROCHE HOLDING LTD.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 260  CHF
Spread / Average Target 4,9%
EPS Revisions
Severin Schwan Chief Executive Officer & Executive Director
Christoph Franz Chairman
Alan Hippe Chief Financial & Information Technology Officer
John Irving Bell Non-Executive Director
Andreas Oeri Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
ROCHE HOLDING LTD.0.39%212 046
JOHNSON & JOHNSON3.24%387 546
PFIZER18.47%250 618
NOVARTIS6.19%221 937
MERCK AND COMPANY33.00%194 612
AMGEN9.47%122 633